News
London's FTSE 100 was set to finish lower on Wednesday for the first time in four weeks, with heavyweight names in the ...
US and Chinese stocks experienced gains amid anticipation for US-China trade discussions and the Federal Reserve's ...
26m
Investor's Business Daily on MSNThe 'Double Whammy' That Sent Sarepta Stock To An Eight-Year LowSarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA ...
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...
Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...
“Potential exposure to these substances is still quite small, thank goodness,” Jim Crotty, who served for over a decade in ...
The FTSE 100’s record run was poised to come to an end on Wednesday as pharma stocks slumped on the back of a controversial ...
3h
TipRanks on MSNSarepta price target lowered to $70 from $110 at Piper SandlerPiper Sandler lowered the firm’s price target on Sarepta (SRPT) to $70 from $110 and keeps an Overweight rating on the shares. The firm notes Tuesday has been “a doozy of a day” for Sarepta, with the ...
In today's newsletter: India launches airstrikes inside Pakistan in an escalation of tensions between the two counties. The ...
Canada's new prime minister, Mark Carney, is meeting with President Donald Trump in the Oval Office, a week after winning the ...
Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...
The latest on trade talks, Real ID requirements for travel, pharma stocks tumble, and more news to start your day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results